Association between the preoperative neutrophil-to-lymphocyte ratio and tertiary lymphoid structures surrounding tumor in gastric cancer.
gastric cancer
neutrophil-to-lymphocyte ratio
tertiary lymphoid structure
tumor infiltrating lymphocytes
tumor-associated neutrophils
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
10
09
2020
accepted:
12
02
2021
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
9
3
2021
Statut:
ppublish
Résumé
The neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated with a poor prognosis in various types of cancer. We previously reported that an antitumor immune response was induced by tertiary lymphoid structures (TLSs) surrounding tumor, and increased TLS was an independent prognostic factor in patients with gastric cancer. The present study examined the stratification based on the correlation between the preoperative NLR and TLS density in gastric cancer. A total of 199 patients who underwent surgery for stage Ib-IV gastric cancer were included in the study. Receiver operating characteristic curve analysis was used to determine the appropriate cut-off values of the preoperative NLR and the TLS density. The prognostic factors were evaluated in a multivariate analysis. The median NLR was 2.18 (mean ± SD, 2.7±2.04). A total of 91 patients with an NLR ≥2.33 was classified into the high NLR group. The overall survival was significantly improved in patients with a low NLR than in those with a high NLR. Additionally, the low NLR group tended to have a high TLS density. The multivariate analysis indicated that the preoperative NLR and TLS density were independent risk factors. When the patients were classified into the high and low NLR and TLS groups and the survival rates were compared, the prognosis was significantly improved in the low NLR and high TLS group than in the other groups. The preoperative NLR may be associated with the presence of TLSs surrounding the tumor, and the combination of NLR and TLS may be useful for the stratification of patient prognosis. The present results suggested that the NLR and TLS density may be surrogate markers for immunotherapy against gastric cancer.
Identifiants
pubmed: 33680464
doi: 10.3892/mco.2021.2238
pii: MCO-0-0-02238
pmc: PMC7922788
doi:
Types de publication
Journal Article
Langues
eng
Pagination
76Informations de copyright
Copyright: © Yamakoshi et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Medicine (Baltimore). 2015 Mar;94(11):e639
pubmed: 25789957
Rev Assoc Med Bras (1992). 2017 Dec;63(12):1065-1068
pubmed: 29489971
Surg Today. 2014 Nov;44(11):2146-52
pubmed: 24831660
Ann Surg Oncol. 2017 Nov;24(12):3763-3770
pubmed: 28160141
Clin Cancer Res. 2008 Aug 15;14(16):5220-7
pubmed: 18698040
HPB (Oxford). 2018 May;20(5):379-384
pubmed: 29336893
Clin Exp Metastasis. 2016 Oct;33(7):727-39
pubmed: 27449756
Eur J Gastroenterol Hepatol. 2016 May;28(5):493-502
pubmed: 26854795
Cancers (Basel). 2014 Apr 23;6(2):969-97
pubmed: 24762633
Ann Surg Oncol. 2017 Oct;24(11):3456-3462
pubmed: 28718035
BMC Cancer. 2001;1:7
pubmed: 11481031
Semin Immunol. 2008 Feb;20(1):26-42
pubmed: 18243731
J Surg Res. 2017 Jul;215:74-82
pubmed: 28688665
Nat Rev Cancer. 2019 Jun;19(6):307-325
pubmed: 31092904
Cancer Immunol Immunother. 2013 Nov;62(11):1745-56
pubmed: 24092389
Nature. 2020 Jan;577(7791):549-555
pubmed: 31942075
BMC Immunol. 2018 Apr 16;19(1):13
pubmed: 29661142
Anticancer Res. 2020 May;40(5):2881-2887
pubmed: 32366438
Oncoimmunology. 2015 Jun 3;5(2):e1054598
pubmed: 27057426
PLoS One. 2014 Nov 17;9(11):e111906
pubmed: 25401500
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
BMC Cancer. 2017 Nov 10;17(1):744
pubmed: 29126400
Int J Clin Oncol. 2017 Jun;22(3):469-475
pubmed: 28097441
Surg Today. 2016 Apr;46(4):405-13
pubmed: 26036223
Oncol Rep. 2020 Jan;43(1):251-259
pubmed: 31746403
Am J Surg. 2017 Nov;214(5):938-944
pubmed: 28830617
Eur J Gastroenterol Hepatol. 2019 Sep;31(9):1110-1115
pubmed: 30888972
Anticancer Res. 2014 Dec;34(12):7129-36
pubmed: 25503140
Dig Surg. 2014;31(4-5):327-33
pubmed: 25471697
BMC Cancer. 2015 Sep 04;15:617
pubmed: 26341881
J Oncol. 2019 Sep 24;2019:1079710
pubmed: 31662748
Nature. 2020 Jan;577(7791):561-565
pubmed: 31942071
Aging Male. 2019 Jun 28;:1-5
pubmed: 31250688
Cancer Cell. 2009 Sep 8;16(3):183-94
pubmed: 19732719
Gastric Cancer. 2017 Jul;20(4):602-611
pubmed: 27665104
Ann Oncol. 2016 Mar;27(3):494-501
pubmed: 26673353
BMC Cancer. 2018 Dec 17;18(1):1261
pubmed: 30558575
Dis Colon Rectum. 2019 Apr;62(4):498-508
pubmed: 30844974
P R Health Sci J. 2019 Mar;38(1):60-63
pubmed: 30924917
J Gastric Cancer. 2019 Sep;19(3):254-277
pubmed: 31598370
Virchows Arch. 2020 Dec;477(6):807-816
pubmed: 32483662
J Surg Oncol. 2017 Mar;115(4):470-479
pubmed: 28105646
Am J Respir Crit Care Med. 2014 Apr 1;189(7):832-44
pubmed: 24484236
Front Immunol. 2016 Oct 03;7:407
pubmed: 27752258
BMC Cancer. 2015 Mar 06;15:101
pubmed: 25884667
Intest Res. 2021 Jan;19(1):62-70
pubmed: 32375208
Int J Oncol. 2020 Jul;57(1):171-182
pubmed: 32319601
PLoS One. 2016 May 20;11(5):e0156101
pubmed: 27203425
Medicine (Baltimore). 2016 Feb;95(6):e2689
pubmed: 26871799
Anticancer Res. 2018 Jun;38(6):3745-3751
pubmed: 29848737
Afr Health Sci. 2019 Mar;19(1):1602-1606
pubmed: 31148989
Lancet. 2017 Dec 2;390(10111):2461-2471
pubmed: 28993052